Tyrosine kinase inhibitors (TKIs) represent a major milestone in the treatment of ALK rearrangement‐positive NSCLC patients, playing a crucial role in combating these oncogenic alterations [10, 11, 12]. Here, ALK is linked to non-small cell lung carcinoma.